Mukesh Harisinghani, MD
Associate Professor of Radiology, Harvard Medical School Assistant Radiologist, Dept. of Abdominal Imaging Phone: 617-726-8396 Email: mharisinghani@mgh.harvard.edu Design and conduct clinical trials and provide an avenue for clinical testing of novel imaging agents developed at CMIR. Over the last several years we have conducted phase 1,2 and phase 3 clinical trials of monocrystalline iron oxides (1-2) for a number of applications. Current trials evaluate the efficacy of these agents to improve detection of subtle lymph node metastases in patients with prostate cancer (funded in part by RSNA) and renal cancer (funded in part by by SCBT). My primary clinical interests lie in abdominal and pelvic MR imaging Publications Nanoparticle-enhanced MRI: are we there yet?
Lancet Oncol. 2008;9:814-815
The potential of nanoparticle-enhanced imaging.
Urol Oncol. 2008;26(1):65-73
Pilot Study Evaluating Use of Lymphotrophic Nanoparticle-Enhanced Magnetic Resonance Imaging for Assessing Lymph Nodes in Renal Cell Cancer.
Urology. 2008;71(4):708-12
Enhancement Characteristics of Ultrasmall Superparamagnetic Iron Oxide Particle Within the Prostate Gland in Patients With Primary Prostate Cancer.
J Comput Assist Tomogr. 2008;32:523-528
Utility of a New Bolus-Injectable Nanoparticle for Clinical Cancer Staging
Neoplasia. 2007;(9)12:1160-1165
Comparison of lymphotropic nanoparticle-enhanced MRI sequences in patients with various primary cancers.
Am J Roentgenol. 2006;187(6):W582-8
Ferumoxtran-10-Enhanced MR Lymphangiography: Does Contrast-Enhanced Imaging Alone Suffice for Accurate Lymph Node Characterization?
Am J Roentgenol. 2006;186(1):144-8
Lymphotropic nanoparticle enhanced MR imaging (LNMRI) technique for lymph node imaging.
Eur J Radiol. 2006;58(3):367-74
Prostate cancer imaging-what the urologic oncologist needs to know.
Radiol Clin North Am. 2006;44(5):711-22
New clinical imaging modalities in prostate cancer.
Hematol Oncol Clin North Am. 2006;20(4):811-30
Lymphotrophic nanoparticle enhanced MR imaging (LNMRI) for lymph node imaging.
Abdom Imaging. 2006;:ePub
Mapping of nodal disease in locally advanced prostate cancer: Rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy
Int J Radiat Oncol. 2005;63(4):1262-9
A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation.
Urology. 2005;66(5):1066-71
Sensitive, noninvasive detection of lymph node metastases.
PLoS Med. 2004;1(3):e66
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer
N Engl J Med. 2003;348:2491-9
MR lymphangiography for detection of minimal nodal disease in patients with prostate cancer
Acad Radiol. 2002;9 Suppl 2:S312-3
Splenic imaging with ultrasmall superparamagnetic iron oxide ferumoxtran-10 (AMI-7227): preliminary observations
J Comput Assist Tomogr. 2001;25:770-6
MRI contrast agents for evaluating focal hepatic lesions
Clin Radiol. 2001;56:714-25
MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation
Am J Roentgenol. 1999;172:1347-51
MR imaging of the liver with Gd-BOPTA: quantitative analysis of T1-weighted images at two different doses
J Magn Reson Imaging. 1999;10:80-3
|

Mukesh Harisinghani, MD